scorecardresearchInnova Captab files draft papers for IPO with Sebi

Innova Captab files draft papers for IPO with Sebi

Updated: 30 Jun 2022, 07:55 AM IST
TL;DR.

The proposed IPO comprises fresh issuance of equity shares worth 400 crore and an Offer For Sale (OFS) of 96 lakh equity shares by promoters and other shareholders, according to the Draft Red Herring Prospectus (DRHP).

Madhabi Puri Buch, Chairperson of Securities and Exchange Board of India (SEBI), poses for a picture at the SEBI headquarters in Mumbai, India, May 27, 2022. REUTERS/Francis Mascarenhas

Madhabi Puri Buch, Chairperson of Securities and Exchange Board of India (SEBI), poses for a picture at the SEBI headquarters in Mumbai, India, May 27, 2022. REUTERS/Francis Mascarenhas

(PTI) Pharmaceutical company Innova Captab Ltd has filed preliminary papers with the capital markets regulator Sebi to raise as much as 900 crore through an Initial Public Offering (IPO).

The proposed IPO comprises fresh issuance of equity shares worth 400 crore and an Offer For Sale (OFS) of 96 lakh equity shares by promoters and other shareholders, according to the Draft Red Herring Prospectus (DRHP).

As part of the OFS, Manoj Kumar Lohariwala, Vinay Kumar Lohariwala and Gian Parkash Aggarwal will sell 32 lakh shares each.

At present, promoters -- Manoj and Vinay -- hold 39.66 per cent and 30.08 per cent stake, respectively, in the company, while Gian owns a 30.23 per cent holding in the pharma firm.

Besides, the company may consider pre-IPO placement of equity shares aggregating up to 80 crore. If such a placement is undertaken, the size of the fresh issue will be reduced.

According to market sources, the initial share sale is expected to raise anywhere between 700 crore and 900 crore.

Out of the 400 crore proposed to be raised through fresh issuance of equity shares, 180.5 crore will be used for payment of debt and 29.5 crore will be utilised for payment of loans availed by its subsidiary UML.

The Haryana-based Innova Captab is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.

The company's business includes providing research, product development and manufacturing services to Indian pharmaceutical firms, domestic branded generics as well as international branded generics businesses. It has two manufacturing facilities in Baddi, Himachal Pradesh and a new facility is to come up in Jammu.

The companies revenue from operations rose 10 per cent to 410.66 crore in fiscal 2021 from 373.32 crore in the preceding fiscal. Profit after tax grew 23.70 per cent to 34.50 crore in fiscal 2021 from 27.89 crore in fiscal 2020.

ICICI Securities Limited and JM Financial Limited have been appointed as merchant bankers to manage the company's IPO.

Article
An IPO is the process by which a private company can go public by offering its stock to the general public for the first time.
First Published: 30 Jun 2022, 07:55 AM IST